Increased levels of serum serglycin and agrin is associated with adverse perinatal outcome in early onset preeclampsia

Basit Öğe Kaydı
dc.authoridBaşak Gümüş Güler / 0000-0002-0182-6774
dc.authorscopusidBaşak Gümüş Güler / 57193546825
dc.authorwosidBaşak Gümüş Güler / JHA-5039-2023
dc.contributor.authorGümüş Güler, Başak
dc.contributor.authorÖzler, Sibel
dc.date.accessioned2020-08-30T20:06:50Z
dc.date.available2020-08-30T20:06:50Z
dc.date.issued2019
dc.departmentİstinye Üniversitesi, Sağlık Bilimleri Fakültesi, Hemşirelik Bölümüen_US
dc.description.abstractGoal: Our aim was to determine whether alterations in serum serglycin and agrin levels in early-onset preeclampsia (EOPE) are useful in predicting adverse perinatal outcomes such as fetal growth restriction (FGR), intrauterine fetal demise (IUFD), preterm delivery and/or neonatal unit admission. Materials and Methods: A prospective case-controlled study enrolled 88 pregnant patients (44 EOPE and 44 controls). Maternal serum serglycin and agrin levels were determined before the 34th gestational week by enzyme-linked immunosorbent assay. Results: Compared with controls, women with EOPE had significantly higher serglycin and agrin levels (p = .018; p = .048). Multivariable logistic regression analysis revealed serglycin was independently associated with FGR in EOPE (OR 0.866; 95% CI 0.779-0.953). Agrin was independently associated with IUFD in EOPE (OR 0.757, 95% CI 0.636-0.879). Conclusions: The current study suggests that increased maternal serum serglycin is associated with FGR, and increased maternal serum agrin is associated with IUFD in EOPE.en_US
dc.identifier.citationGumus Guler, B., & Ozler, S. (2019). Increased levels of serum serglycin and agrin is associated with adverse perinatal outcome in early onset preeclampsia. Fetal and pediatric pathology, 38(5), 418-431.en_US
dc.identifier.doi10.1080/15513815.2019.1604922en_US
dc.identifier.endpage431en_US
dc.identifier.issn1551-3815en_US
dc.identifier.issn1551-3823en_US
dc.identifier.issue5en_US
dc.identifier.pmid31018746en_US
dc.identifier.scopus2-s2.0-85064811109en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage418en_US
dc.identifier.urihttps://doi.org/10.1080/15513815.2019.1604922
dc.identifier.urihttps://hdl.handle.net/20.500.12713/633
dc.identifier.volume38en_US
dc.identifier.wosWOS:000470444700001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorGümüş Güler, Başaken_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofFetal and Pediatric Pathologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEarly Onset Preeclampsiaen_US
dc.subjectSerglycinen_US
dc.subjectAgrinen_US
dc.subjectFetal Growth Restrictionen_US
dc.subjectIntrauterine Fetal Demiseen_US
dc.subjectAdverse Perinatalen_US
dc.subjectMaternal Outcomesen_US
dc.titleIncreased levels of serum serglycin and agrin is associated with adverse perinatal outcome in early onset preeclampsiaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
175.pdf
Boyut:
1.14 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Hemşirelik Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu